share_log

This Brown & Brown Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

This Brown & Brown Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

這位Brown & Brown分析師不再看好;以下是星期二的五大下調。
Benzinga ·  03/25 14:57

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

頂級華爾街分析師改變了對這些知名公司的看法。有關所有分析師評級變更的完整信息,包括上調、下調和開始覆蓋,請查看我們的分析師評級頁面。

  • Morgan Stanley analyst Bob Huang downgraded the rating for Brown & Brown, Inc. (NYSE:BRO) from Overweight to Equal-Weight and maintained the price target of $128. Brown & Brown shares closed at $120.98 on Monday. See how other analysts view this stock.
  • Jefferies analyst Surinder Thind downgraded Dun & Bradstreet Holdings, Inc. (NYSE:DNB) from Buy to Hold and cut the price target from $11 to $9.15. Dun & Bradstreet shares closed at $8.99 on Monday. See how other analysts view this stock.
  • Leerink Partners analyst Marc Goodman downgraded Opthea Limited (NASDAQ:OPT) from Outperform to Market Perform and lowered the price target from $12 to $1. Opthea shares closed at $3.36 on Monday. See how other analysts view this stock.
  • Citigroup analyst Anthony Pettinari downgraded the rating for The AZEK Company Inc. (NYSE:AZEK) from Buy to Neutral and lowered the price target from $61 to $51.5. AZEK shares closed at $48.56 on Monday. See how other analysts view this stock.
  • Stephens & Co. analyst Mason Carrico downgraded Akoya Biosciences, Inc. (NASDAQ:AKYA) from Overweight to Equal-Weight and slashed the price target from $3.5 to $1.8. Akoya Biosciences shares closed at $1.67 on Monday. See how other analysts view this stock.
  • 摩根士丹利分析師Bob Huang將Brown & Brown, Inc. (紐交所:BRO)的評級從超配下調至等權重,並維持價格目標爲128美元。Brown & Brown的股價週一收於120.98美元。看看其他分析師如何看待這隻股票。
  • Jefferies分析師Surinder Thind將鄧白氏控股公司 (紐交所:DNB) 的評級從買入下調至持有,並將價格目標從11美元下調至9.15美元。鄧白氏的股價週一收於8.99美元。看看其他分析師如何看待這隻股票。
  • Leerink Partners分析師Marc Goodman將Opthea Limited (納斯達克:OPT)的評級從表現優於大盤下調至市場表現,並將價格目標從12美元下調至1美元。Opthea的股價週一收於3.36美元。看看其他分析師如何看待這隻股票。
  • 花旗集團分析師Anthony Pettinari將The AZEK Company Inc. (紐交所:AZEK)的評級從買入下調至中立,並將價格目標從61美元下調至51.5美元。AZEK的股價週一收於48.56美元。看看其他分析師如何看待這隻股票。
  • Stephens & Co.分析師Mason Carrico將Akoya Biosciences, Inc. (納斯達克:AKYA)的評級從超配下調至等權重,並將價格目標從3.5美元下調至1.8美元。Akoya Biosciences的股價週一收於1.67美元。看看其他分析師如何看待這隻股票。

Considering buying BRO stock? Here's what analysts think:

考慮購買BRO股票嗎?以下是分析師的看法:

Read This Next:

閱讀下一篇:

  • Wall Street's Most Accurate Analysts Spotlight On 3 Industrials Stocks Delivering High-Dividend Yields
  • 華爾街最準確的分析師聚焦於三只提供高分紅收益率的工業股票

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 294

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。